Guangzhou Magpie Pharmaceutical

Guangzhou Magpie Pharmaceutical is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs for the treatment of neurodegenerative and cardiovascular diseases. The company utilizes a proprietary Multi-Target Directed Ligands (MTDL) design platform to create first-in-class or best-in-class therapies that address the complex pathology of chronic diseases. Its lead candidate, T-006, is being evaluated in clinical trials for indications including Parkinson's disease, Alzheimer's disease, and ischemic stroke. Magpie Pharma aims to provide breakthrough treatments for conditions with significant unmet medical needs through its unique medicinal chemistry approach that combines multiple pharmacophores into single molecules.